MetaCap

Abivax SA (ABVX) vs Supernus (SUPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Supernus (SUPN) has outperformed Abivax SA (ABVX) over the past year, losing 36.9% versus a loss of 38.5%. Abivax SA is the larger company by market cap ($6.41 billion vs $5.94 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVX-38.55%SUPN-36.87%
+28%-9%-46%
Nov 21, 20251 yearNov 20, 2026
ABVX+781.93%SUPN+17.69%
+1727%+803%-120%
Oct 16, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVX versus SUPN key metrics
MetricABVXSUPN
Share price$73.20$28.61
Market cap$6.41B$5.94B
1-day change-9.24%+0.92%
YTD return-45.72%-42.43%
1-year return-38.55%-36.87%
5-year return—-6.53%
Forward P/E—7.15
EPS (TTM)$-6.08$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$718.95M
Revenue growth (YoY)—+8.63%
Net income (latest FY)—$-38.55M
Gross margin—89.63%
Operating margin—-8.66%
Net margin—-5.36%
52-week high$148.83$42.81
52-week low$62.70$25.92
Distance from 52-week high-50.82%-33.17%
Analyst consensusnonestrong_buy
Avg. price target upside+123.47%+89.23%
Average volume1.35M2.77M
Shares outstanding87.54M207.72M
Employees98827
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Abivax SA

ABVX stock →

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Supernus

SUPN stock →

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees

ABVX vs SUPN FAQ

Which is bigger, Abivax SA or Supernus?

Abivax SA (ABVX) is larger, with a market capitalization of $6.41B compared with $5.94B for Supernus (SUPN).

Which stock has performed better over the past year, ABVX or SUPN?

SUPN returned -36.87% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.

Are Abivax SA and Supernus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons